bioRxivImmunologyPreprint
Attenuation of endothelial glycocalyx shedding and endocan modulation by Sulodexide in murine models of anaphylaxis.
Lucia Palacio-GarcíaiD, Sergio Fernández‐BravoiD, Irene De Maria-CamachoiD, Irene San Sebastián-JarabaiD, María José Fernández-Gómez, Óscar López-PéreziD, Sandra Sanz-Andrea, Carlos Pastor‐VargasiD, Emilio Nuñez‐BorqueiD, José Julio LagunaiD, Marcela Valverde‐MongeiD, Luis Miguel Blanco‐ColioiD, Vanesa EstebaniD, Nerea Méndez‐BarberoiD
Abstract
BackgroundAnaphylaxis is an acute life-threatening reaction. Research into the vascular endothelium and its components may improve disease management and patient outcomes. ObjectiveWe investigated the endothelial glycocalyx (eGCX) and its pathophysiological role in murine anaphylaxis, aiming to identify novel diagnostic and therapeutic targets. MethodsActive systemic anaphylaxis (ASA) and passive systemic anaphylaxis (IgE-PSA and IgG1-PSA) models were evaluated in mice. Sulodexide (Sdx) was administered as a prophylactic treatment. eGCX structure and N-acetylglucosamine residues in mouse aortic tissue were analyzed by electron microscopy and wheat germ agglutinin (WGA) staining. Endocan (ESM-1) levels in mouse aorta and plasma were determined by immunofluorescence and ELISA. Human sera from beta-lactam-induced anaphylaxis and endothelial cell (EC) secretome samples were also analyzed. ResultsASA, IgE-PSA, and IgG1-PSA models showed reduced eGCX surface area and thickness. N-acetylglucosamine and ESM-1 levels decreased in aortic tissue but increased in plasma, indicating glycocalyx shedding. Consistently, ESM-1 secretion was enhanced in ECs exposed to acute anaphylactic sera. ESM-1 and hyaluronic acid levels differed significantly between anaphylactic patients and non-allergic controls. Sdx reduced reaction severity in ASA and IgE-PSA, increased survival in ASA, and prevented eGCX disruption and ESM-1 release. ConclusionseGCX shedding, particularly of ESM-1, acts as a key mediator in murine anaphylaxis. Sdx prophylaxis protects against severe reactions and improves survival. Clinical ImplicationTherapies based on glycosaminoglycans and proteoglycans may mitigate anaphylaxis severity, and monitoring eGCX dynamics could aid diagnosis. Capsule summaryEndothelial glycocalyx shedding contributes to anaphylaxis pathophysiology; targeting its preservation and measuring HA and ESM1 may offer novel diagnostic and therapeutic strategies for clinicians.
- organism: mouse
- assay: imaging
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Butyrate, valerate, and niacin ameliorate anaphylaxis by suppressing IgE-dependent mast cell activation: Roles of GPR109A, PGE2, and epigenetic regulation
K. Nagata, D. Ando, … C. Nishiyama·bioRxiv·Feb 19, 2023
- Circulating miR-29a as a new biomarker of food anaphylaxis and endothelial glycocalyx regulation
Antonio Muñoz-Callejas, Adrian Moreno-Vidal, … Vanesa Esteban·bioRxiv·Apr 8, 2026
- Protective role of protease-activated receptor-2 in anaphylaxis model mice
Maho Nakazawa, Ryota Tochinai, … Shingo Maeda·PLoS ONEPeer-reviewed·Apr 18, 2024
- RAGE antagonist peptide mitigates AGE-mediated endothelial hyperpermeability and accumulation of glycoxidation products in human ascending aortas and in a murine model of aortic aneurysm
C. Camillo, A. Abramov, … G. Ferrari·bioRxiv·Oct 22, 2021
- Co-Therapy with S1P and Heparan Sulfate Derivatives to Restore Endothelial Glycocalyx and Combat Pro-Atherosclerotic Endothelial Dysfunction
Ronodeep Mitra, Kaleigh Pentland, … Eno Essien Ebong·Life SciencesPeer-reviewed·Apr 23, 2025
- Leukocytes have a heparan sulfate glycocalyx that regulates recruitment during inflammation
Megan J. Priestley, Anna K. Hains, … Douglas P. Dyer·Science SignalingPeer-reviewed·Nov 4, 2025